Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

SUVEN LIFE SCIENCES LTD. - 530239 - Closure of Trading Window

 We wish to inform you that the "Trading Window" for dealing in the securities of the Company will be closed for the Designated Persons, their immediate relatives and covered under the said Code of the Company from 1st July, 2019 and the same will remain closed till 48 hours after the declaration of Financial Results for the first quarter ending 30th June, 2019, to the public, in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015. The Board Meeting for approving the Financial Results for the quarter ending 30th June, 2019 will be held on or before 14th August, 2019.
01-07-2019
Bigul

Suven Life Sciences Ltd - 530239 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

 Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions on a consolidated basis and balances for the year ended March 31, 2019.
20-06-2019
Bigul

SUVEN LIFE SCIENCES LTD. - 530239 - Reg.24(A)-Annual Secretarial Compliance

 Annual Secretarial Compliance Report Sr. No. Particulars Details 1Period for which the report has been issued 31/03/2019 2Date of Report30/05/2019 3 Name of the Certifying Firm DVMGOPAL & ASSOCIATES 4 Name of the Certifying Individual DVM GOPAL 5Membership TypeFCS 6 Membership Number 6280 7 CP No. 6798 8 Whether any observations/qualification reported by the Secretarial Auditor ? NO
30-05-2019
Bigul

SUVEN LIFE SCIENCES LTD. - 530239 - Fixes Book Closure for AGM

 Suven Life Sciences Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from August 12, 2019 to August 14, 2019 (both days inclusive) for the purpose of 30th Annual General Meeting (AGM) of the Company to be held on August 14, 2019.
28-05-2019
Bigul

Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 We wish to inform you that senior management team of Suven Life Sciences is giving corporate presentation in 'B&K;''s Annual Global Investor Conference Trinity India 2019' with fund managers and analysts meet organized in Mumbai by B&K; Securities on 29th May, 2019.
27-05-2019
Bigul

SUVEN LIFE SCIENCES LTD. - 530239 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Please find attached Investor Presentation
25-05-2019
Bigul

Suven Life Sciences Ltd - 530239 - Audited Standalone And Consolidated Financial Results Under Ind AS For The Quarter And For The Financial Year Ended 31St March, 2019

 With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 25th May, 2019, has taken on record and approved the Audited Standalone and Consolidated Financial Results of the Company under Ind AS for the quarter and for the year ended 31st March, 2019 and approved the following matters.
25-05-2019
Bigul

Annual report for Suven Life Sciences Ltd. for FY-2019
25-05-2019
Bigul

Company news: Suven Life Sciences

 Suven Life Sciences, a specialty biopharmaceutical company developing therapeutics in central nervous system diseases, on Thursday announced that the
23-05-2019
Bigul

Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Suven Life Sciences Ltd Announces the last patient last visit (LPLV) in their Phase 2 study of Masupirdine (SUVN-502) for Moderate Alzheimer's Disease Top-Line Phase 2 Data is on track to be presented at Alzheimer's Association International Conference at Los Angeles on 17th July 2019
23-05-2019
Next Page
Close

Let's Open Free Demat Account